Sakar Healthcare (SAKAR) | Stock Overview & Key Data
Sakar Healthcare Performance Comparison
Stock Range
Today's Range
Low: ₹331.00
High: ₹339.95
on August 22, 2025
52 Week Range
Low: ₹210.10
High: ₹380.80
on March 28, 2025
on June 19, 2025
All-Time High: ₹479.00 on January 22, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR7.0B
EPS
7.96
P/E Ratio (TTM)
40.28
Forward P/E
N/A
P/B Ratio
2.43
PEG Ratio
N/A
Div. Yield
N/A
ROE
6.13%
Beta
0.064
Debt to Equity
30.26
Financial Highlights
Profitability
Gross Margin
70.80%
Operating Margin
13.53%
Profit Margin
10.45%
Returns and Earnings
Return on Assets (TTM)
4.21%
Return on Equity (TTM)
6.13%
EBITDA
INR510.0M
Net Income (TTM)
INR197.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR86.98
Quarterly Revenue Growth (YoY)
28.20%
Quarterly Earnings Growth (YoY)
93.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sakar Healthcare SAKAR | 6.97B Small-cap | 2.69% | -8.53% | 7.51% | 34.45% | 10.06% | 4.85% | 58.94% | 483.39% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | -2.16% | -4.47% | 0.14% | -13.13% | -7.54% | 86.54% | 195.42% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -0.21% | -6.98% | -5.91% | 7.87% | 1.29% | 26.68% | 71.47% | 87.96% |
| Sun Pharma Advanced SPARC | 47.77B Small-cap | 1.72% | -7.23% | -10.11% | 14.74% | -27.21% | -34.43% | -37.13% | -23.18% |
| Aarti Drugs AARTIDRUGS | 42.99B Small-cap | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% | -14.34% | 10.27% | -34.08% |
| Sequent Scientific SEQUENT | 44.30B Small-cap | 0.12% | -6.92% | -2.35% | 12.64% | -4.77% | 5.41% | 52.52% | 30.60% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
7K
Average 90-Day Volume
12K
Sakar Healthcare Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sakar Healthcare would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SAKAR's 52-week high and low?
- In the last 52 weeks, Sakar Healthcare reached a high of ₹380.80 (on June 19, 2025) and a low of ₹210.10 (on March 28, 2025).
- What is the market cap and P/E ratio for SAKAR?
- Curious about Sakar Healthcare's size and valuation? Its market capitalization stands at 6.97B. When it comes to valuation, the P/E ratio (trailing twelve months) is 40.28, and the forward P/E (looking ahead) is N/A.
- Does SAKAR pay dividends? If so, what's the yield?
- As for dividends, Sakar Healthcare isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sakar Healthcare's main competitors or similar companies to consider before investing?
When looking at Sakar Healthcare, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -7.54% 86.54% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 26.68% 71.47% Sun Pharma Advanced
SPARC47.77B Healthcare Drug Manufacturers - Specialty & Generic -34.43% -37.13% Aarti Drugs
AARTIDRUGS42.99B Healthcare Drug Manufacturers - Specialty & Generic -14.34% 10.27% Sequent Scientific
SEQUENT44.30B Healthcare Drug Manufacturers - Specialty & Generic 5.41% 52.52% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sakar Healthcare Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sakar Healthcare's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.13%, the Debt to Equity ratio from the most recent quarter is 30.26, and its Gross Profit Margin stands at 70.80%.
- What is the recent revenue and earnings growth for SAKAR?
- Looking at Sakar Healthcare's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 28.20%, and quarterly earnings saw a YoY growth of 93.70%.
- How much of SAKAR stock is held by insiders and institutions?
- Wondering who owns Sakar Healthcare stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.